Medical management of primary hyperparathyroidism: Proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3607-3618

  Marcocci, Claudio ^a   Bollerslev, Jens ^b   Khan, Aliya Aziz ^c   Shoback, Dolores Marie ^d  

^a UNIVERSITY OF PISA   (Italy)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; CONJUGATED ESTROGEN; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; VITAMIN D; VITAMIN;

ARTHRALGIA; ASYMPTOMATIC DISEASE; ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; HORMONE BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; PARATHYROIDECTOMY; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT REFUSAL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ASYMPTOMATIC DISEASES; CONSENSUS DEVELOPMENT; DIET SUPPLEMENTATION; EDUCATION; ENDOCRINOLOGY; HYPERPARATHYROIDISM, PRIMARY; PRACTICE GUIDELINE; STANDARDS;

ASYMPTOMATIC DISEASES; CALCIUM; DIETARY SUPPLEMENTS; EDUCATION; ENDOCRINOLOGY; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PRACTICE GUIDELINES AS TOPIC; VITAMIN D; VITAMINS;

EID: 84907637552     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1417     Document Type: Conference Paper

References (71)

1. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93:3462-3470.
2. Fraser WD. Hyperparathyroidism. Lancet. 2009;374:145-158.
3. Silver J, Sela SB, Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens. 1997;6:321-326.
4. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest. 1995;96:1786-1793.
5. Paik JM, Curhan GC, Taylor EN. Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ. 2012;345:e6390.
6. Chiavistelli S, Bilezikian J. Does calcium intake influence the development of primary hyperparathyroidism. IBMS Bone KEy. 2013;10:314. http://www.nature.com/bonekey/knowledgeenvironment/2013/130424/bonekey201348/full/bonekey201348.html. Published April 24, 2013. Accessed July 9, 2014.
7. Locker FG, Silverberg SJ, Bilezikian JP. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med. 1997;102:543-550.
8. Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. Eur J Nutr. 2002;41:258-263.
9. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. In: Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Committee to Review Dietary Reference Intakes for Calcium and Vitamin. Washington, DC: The National Academies Press; 2011.
10. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-58.
11. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
12. Vieth R. Why the minimum desirable serum 25-hydroxy vitamin D level should be 75 nmol/L (30ng/ml). Best Pract Res Clin Endocrinol Metab. 2011;25:681-691.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
14. Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011;165:851-864.
15. Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007;22(suppl 2):V100-V104.
16. Rao DS, Agarwal G, Talpos GB, et al. Role of vitamin Dand calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res. 2002;17(suppl 2):N75-N80.
17. Bollerslev J, Rolighed L, Mosekilde L. Mild primary hyperparathyroidism and metabolism of vitamin D. IBMS BoneKEy. 2011;8:342-351. http://www.nature.com/bonekey/knowledgeenvironment/2011/1107/bonekey20110522/full/bonekey20110522.html. Published July, 2011. Accessed July 9, 2014.
18. Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000;85:1054-1058.
19. Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2008;68:707-715.
20. Stein EM, Dempster DW, Udesky J, et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone. 2011;48:557-561.
21. Farahnak P, Lärfars G, Sten-Linder M, Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J Clin Endocrinol Metab. 2011;96:2112-2118.
22. Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95:2172-2179.
23. Persson A, Bollerslev J, Rosen T, et al. Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism. Clin Endocrinol (Oxf). 2011;74:174-180.
24. 3 and parathyroid hormone. J Cell Biochem. 2003;88:234-237.
25. Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a metaanalysis. J Clin Endocrinol Metab. 2005;90:1525-1530.
26. Amstrup AK, Rejnmark L, Vestergaard P, et al. Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls - a cross-sectional study. Clin Endocrinol (Oxf). 2011;74:130-136.
27. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. 2005;90:2122-2126.
28. Lind L, Wengle B, Sørensen OH, Wide L, Akerström G, Ljunghall S. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism. Acta Endocrinol (Copenh). 1989;120:250-256.
29. Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol. 2009;161:189-193.
30. Isidro ML, Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine. 2009;36:305-310.
31. Stewart ZA, Blackford A, Somervell H, et al. 25-Hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery. 2005;138:1018-1025; discussion 1025-1026.
32. Marcus R, Madvig P, Crim M, Pont A, Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med. 1984;100:633-640.
33. Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med. 1986;314:1481-1485.
34. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med. 1996;125:360-368.
35. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:1174-1178.
36. Zanchetta JR, Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res. 2001;16:189-190.
37. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:581-587.
38. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-3325.
39. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 2002;87:4482-4489.
40. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16:113-119.
41. Khan AA, Bilezikian JP, Kung A, Dubois SJ, Standish TI, Syed ZA. Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract. 2009;15:705-713.
42. Schmidli RS, Wilson I, Espiner EA, Richards AM, Donald RA. Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status. Clin Endocrinol (Oxf). 1990;32:293-300.
43. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab. 1993;77:1067-1071.
44. Díaz Guardiola P, Vega Piñero B, Alameda Hernando C, Pavón de Paz I, Iglesias Bolaños P, Guijarro de Armas G. Primary hyperparathyroidism. An alternative to the surgery [in Spanish]. Endocrinol Nutr. 2009;56:132-135.
45. Nemeth EF, Shoback D. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Best Pract Res Clin Endocrinol Metab. 2013;27:373-384.
46. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760-771.
47. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3803-3808.
48. Khan A, Grey A, Shoback D. Medical management of a symptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:373-381.
49. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135-141.
50. Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009;94:4860-4867.
51. Arranz Martín A, Azcárate Villalón A, Luque Ramírez M, et al. Low-dose cinacalcet reduces serum calciuminpatients with primary hyperparathyroidism not eligible for surgery]in Spanish]. Endocrinol Nutr. 2011;58:24-31.
52. Cetani F, Saponaro F, Banti C, et al. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Invest. 2012;35:655-660.
53. Filopanti M, Verga U, Ermetici F, et al. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur J Endocrinol. 2012;167:157-164.
54. Iglesias P, Ais G, González A, et al. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. Am J Med Sci. 2008;335:111-114.
55. Luque-Fernández I, García-Martín A, Luque-Pazos A. Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment. Ther Adv Endocrinol Metab. 2013;4:77-81.
56. Faggiano A, Di Somma C, Ramundo V, et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine. 2011;39:283-287.
57. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57:517-521.
58. Saponaro F, Faggiano A, Grimaldi F, et al. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clin Endocrinol (Oxf). 2013;79:20-26.
59. Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2766-2772.
60. Peacock M, Bilezikian JP, Bolognese MA, et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2011;96:E9-E18.
61. Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery. 2006;140:874-881; discussion 881-872.
62. Zanocco K, Heller M, Sturgeon C. Cost-effectiveness of parathyroidectomy for primary hyperparathyroidism. Endocr Pract. 2011;17(suppl 1):69-74.
63. European Medicines Agency. Mimpara, cinacalcet. http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000570/human-med-000903.jsp&mid=WC0p01ac058001d124. Updated February 19, 2013. Accessed July 9, 2014.
64. US Food and Drug Administration. Sensipar (cinacalcet) tablets. Highlights of prescribing information. www.accessdata.fda.gov/drugsatfda-docs/label/2011/021688s017lbl.pdf. Published August 1, 2011. Accessed July 9, 2014.
65. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. NEngl J Med. 2000;343:1863-1875.
66. Marx SJ. Hyperparathyroid genes: sequences reveal answers and questions. Endocr Pract. 2011;17(suppl 3):18-27.
67. Falchetti A, Cilotti A, Vaggelli L, et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab. 2008;4:351-357.
68. Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol. 2010;2010:906163.
69. Keutgen XM, Buitrago D, Filicori F, et al. Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database. Ann Surg. 2012;255:981-985.
70. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3561-3569.
71. Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab. 2014;99:1072-1080.